News and Events

News

National Hemophilia Foundation Applauds First von Willebrand Disease Clinical Practice Guidelines Issued by NHLBI

May 6, 2008
Read Press Release

To stay informed about the latest news in hematology and bleeding disorders, you or your patients may be interested in hearing the latest news and attending the conferences and meetings listed on this site.

Bookmark this page and check back often for the latest news and events.

Events

CSL Behring will be participating in all of these events, so please stop by our exhibit booth and get information on Stimate^®, speak with a CSL Behring representative, or obtain brochures.

Hemophilia Federation of America
HFA 2009 Annual Educational Symposium
March 13-14, 2009
Mariott East
Indianapolis, IN
www.hemophiliafed.org

Hemophilia & Thrombosis Research Society
2009 HTRS/NASCOLA Annual Scientific Symposium
April 16-18, 2009
Chicago, Illinois
www.htrs.org

International Society on Thrombosis & Haemostasis
XXII ISTH Congress
July 11-17, 2009
Boston Convention & Exhibition Center
Boston, MA
www.isth2009.com

National Hemophilia Foundation
Annual Meeting
October 29-31, 2009
San Francisco, CA
www.hemophilia.org

The American Society of Hematology
51st Annual Meeting and Exposition
December 5-8, 2009
Ernest N. Morial Convention Center
New Orleans, LA
www.hematology.org

Important Safety Information

Stimate^® Nasal Spray is indicated for patients with mild to moderate classic type 1 von Willebrand disease (VWD) with Factor VIII levels greater than 5%. Stimate^® Nasal Spray is not indicated for the treatment of severe classic VWD (type 1) and when there is evidence of an abnormal molecular form of Factor VIII antigen.

Stimate^® Nasal Spray is contraindicated in individuals with a known hypersensitivity to desmopressin or any of the components of Stimate^®. Stimate^® should not be used in patients with type 2B VWD, since platelet aggregation may be induced. Stimate^® Nasal Spray is for intranasal use only.

To decrease the potential for hyponatremia or water intoxication, especially in the young and the elderly, patients using desmopressin who are not in need of antidiuretic hormone for its antidiuretic effect should be cautioned to reduce fluid intake, ingesting only enough to satisfy thirst. Such patients should be monitored for the rare occurrence of an extreme decrease in plasma osmolality that could result in seizures, possibly leading to coma.

Other adverse reactions reported with use of injectable and/or intranasal desmopressin acetate include headache, nausea, somnolence, dizziness, chest pain, palpitations and tachycardia, and severe allergic reactions, including anaphylaxis. See full prescribing information for a complete list of adverse reactions.